购物车
- 全部删除
- 您的购物车当前为空
AZD8931 diFuMaric acid 是一种可逆的 ATP 竞争性 EGFR、ErbB2 和 ErbB3 抑制剂(IC50 分别为 4 nM、3 nM 和 4 nM)。
AZD8931 diFuMaric acid 是一种可逆的 ATP 竞争性 EGFR、ErbB2 和 ErbB3 抑制剂(IC50 分别为 4 nM、3 nM 和 4 nM)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 780 | 现货 | |
5 mg | ¥ 1,750 | 现货 | |
10 mg | ¥ 2,590 | 现货 | |
25 mg | ¥ 4,130 | 现货 | |
50 mg | ¥ 5,590 | 现货 | |
100 mg | ¥ 7,500 | 现货 | |
200 mg | ¥ 9,870 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 2,470 | 现货 |
产品描述 | AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively). |
靶点活性 | ERB3:4 nM, ErbB2:3 nM , EGFR:4 nM |
体内活性 | AZD8931 显著抑制了 IBC 细胞的生长并在体外诱导了人类 IBC 细胞的凋亡。AZD8931 单药疗法抑制了异种移植瘤的生长[1]。 |
动物实验 | Two IBC cell lines SUM149 and FC-IBC-02 。Cell growth and apoptotic cell death were examined in vitro.?For the in vivo tumor growth studies, IBC cells were orthotopically transplanted into the mammary fat pads of immunodeficient mice.?AZD8931 was given by daily oral gavage at doses of 25 mg/kg, 5 days/week for 4 weeks.?Paclitaxel was subcutaneously injected twice weekly[1]. |
别名 | 4-[[4-[(3-氯-2-氟苯基)氨基]-7-甲氧基-6-喹唑啉基]氧基]-N-甲基-1-哌啶乙酰胺二富马酸盐 |
分子量 | 706.1 |
分子式 | C31H33ClFN5O11 |
CAS No. | 1196531-39-1 |
Smiles | OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 30 mg/mL (42.49 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容